Cheaper MS drug could match pricey standard in major trial

NCT ID NCT04688788

Ongoing Disease control Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether rituximab, a cheaper drug, works as well as ocrelizumab for active multiple sclerosis. About 600 adults with relapsing or progressive MS will receive one of the two drugs. The main goal is to see if rituximab can prevent new brain lesions as effectively as ocrelizumab.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rituximab and ocrelizumab (drugs that target immune cells to reduce MS activity)
What this could lead to: If rituximab works as well as ocrelizumab, it could offer a more affordable treatment option for multiple sclerosis.
What could go wrong: This is a non-inferiority trial, so rituximab may turn out to be less effective or have different side effects. Results may not apply to all MS types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACTIVE MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic progressive multiple sclerosis multiple sclerosis primary progressive multiple sclerosis relapsing-remitting multiple sclerosis secondary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS RELAPSING-REMITTING MULTIPLE SCLEROSIS SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS

Contacts and locations

Locations

Danish Multiple Sclerosis Center, Rigshospitalet

Glostrup Municipality, Copenhagen, 2600, Denmark
Department of Neurology, Aalborg University Hospital

Aalborg, 9000, Denmark
Department of Neurology, Aarhus University Hospital

Aarhus, 8200, Denmark
Department of Neurology, Herlev Hospital

Herlev, 2730, Denmark
Department of Neurology, Hospital of South West Jutland, Esbjerg

Esbjerg, 6700, Denmark
Department of Neurology, Hospital of Southern Jutland, Sønderborg

Sønderborg, 6400, Denmark
Department of Neurology, Kolding Hospital

Kolding, 6000, Denmark
Department of Neurology, Nordsjællands Hospital i Hillerød

Hillerød, 3400, Denmark
Department of Neurology, Odense University Hospital

Odense, 5000, Denmark
Department of Neurology, Regionshospitalet Holstebro

Holstebro, 7500, Denmark
Department of neurology, Regionshospitalet Viborg

Viborg, 8800, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.